{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T14:23:59Z","timestamp":1791037439087,"version":"4.1.0"},"publisher-location":"Boston, MA","reference-count":20,"publisher":"Springer US","isbn-type":[{"value":"9781461349600","type":"print"},{"value":"9781461501930","type":"electronic"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002]]},"DOI":"10.1007\/978-1-4615-0193-0_28","type":"book-chapter","created":{"date-parts":[[2011,7,22]],"date-time":"2011-07-22T13:40:04Z","timestamp":1311342004000},"page":"177-184","source":"Crossref","is-referenced-by-count":101,"title":["Cyclooxygenase-2 In Human Pathological Disease"],"prefix":"10.1007","author":[{"given":"Alane","family":"Koki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasir K.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Mark","family":"Woerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J.","family":"Dannenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Seibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madorra","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Isakson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime L.","family":"Masferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"28_CR1","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1096\/fasebj.11.4.9068612","volume":"11","author":"GN Levy","year":"1997","unstructured":"G.N. Levy, Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer, FASEB J. 11:234 (1997).","journal-title":"FASEB J"},{"key":"28_CR2","first-page":"125","volume":"1299","author":"HR Herschman","year":"1996","unstructured":"H.R. Herschman, Prostaglandin synthase-2, Biochem. Biophys. Acta. 1299:125 (1996).","journal-title":"Acta"},{"key":"28_CR3","doi-asserted-by":"publisher","first-page":"12013","DOI":"10.1073\/pnas.91.25.12013","volume":"91","author":"K Seibert","year":"1994","unstructured":"K. Seibert, Y. Zhang, K. Leahy et al., Pharmacological and biochemical demonstration of the role of cyclooxygenase-2 in inflammation and pain, Proc. Natl. Acad. Sci. USA 91:12013 (1994).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"28_CR4","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1096\/fasebj.12.12.1063","volume":"12","author":"RN DuBoise","year":"1998","unstructured":"R.N. DuBoise, R.S. Abramson, L. Crofford, R.A. Gupta, L.S. Simon et al., Cyclooxygenase in biology and disease, FASEB J. 12:1063 (1998).","journal-title":"FASEB J"},{"key":"28_CR5","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0092-8674(00)81988-1","volume":"87","author":"M Oshima","year":"1996","unstructured":"M. Oshima, J.E. Dinchuck, S.L. Kargman, H. Oshima, B. Hancock, et al., Suppression of intestinal polyposis in APC delta 16 knockout mice by inhibition of cyclooxygenase-2 (COX-2), Cell 87:803 (1996).","journal-title":"Cell"},{"key":"28_CR6","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0022-3565(24)34934-1","volume":"290","author":"CC Chan","year":"1999","unstructured":"C.C. Chan, S. Boyce, C. Brideau et al., Rofecoxib [Vioxx, MK-0966; 4-(4\u2019-methylsulfonylphenyl)-3phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles, J. Pharmacol. Exp. Ther. 290:551 (1999).","journal-title":"J. Pharmacol. Exp. Ther"},{"issue":"9","key":"28_CR7","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J","volume":"41","author":"LS Simon","year":"1998","unstructured":"L.S. Simon, F.L. Lanza, P.E. Lipsky et al., Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects, Arthritis Rheum. 41(9):1591 (1998).","journal-title":"Arthritis Rheum"},{"issue":"10","key":"28_CR8","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1517\/13543784.8.10.1623","volume":"8","author":"AT Koki","year":"1999","unstructured":"A.T. Koki, K.M. Leahy, and J.L. Masferrer, Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy, Exp. Opin. Invest. Drugs 8(10):1623 (1999).","journal-title":"Exp. Opin. Invest. Drugs"},{"key":"28_CR9","unstructured":"Renal paper"},{"key":"28_CR10","first-page":"363","volume":"25","author":"JL Masferrer","year":"1996","unstructured":"J.L. Masferrer, P.C. Isakson, and K. Seibert, Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agent that spare the gastrointestinal tract, Gastroeneterol. Clin. North Am. 25:363 (1996).","journal-title":"North Am"},{"key":"28_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1006\/pmed.1995.1017","volume":"24","author":"LJ Marnett","year":"1995","unstructured":"L.J. Marnett, Aspirin and related nonsteroidal anti-inflammatory drugs as chemopreventive agents against colon cancer, Preventive Med. 24:103 (1995).","journal-title":"Preventive Med"},{"key":"28_CR12","first-page":"955","volume":"5","author":"MJ Reeves","year":"1996","unstructured":"M.J. Reeves, P.A. Newcomb, A. Trentham-Dietz, B.E. Storer, and P.L. Remington, Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women, Cancer Epid. Biomark. Prey. 5:955 (1996).","journal-title":"Prey"},{"key":"28_CR13","first-page":"1322","volume":"53","author":"MJ Thun","year":"1993","unstructured":"M.J. Thun, M.M. Namboodiri, E.E. Calle, W.D. Flanders, and C.W. Heath, Aspirin use and risk of fatal cancer, Cancer Res. 53:1322 (1993).","journal-title":"Cancer Res"},{"key":"28_CR14","first-page":"138","volume":"5","author":"RE Harris","year":"1996","unstructured":"R.E. Harris, K.K. Namboodiri, and W.B. Farrar, Nonsteroidal antiinflammatory drugs and breast cancer, Epidemiol. 5:138 (1996).","journal-title":"Epidemiol"},{"key":"28_CR15","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/00001648-199403000-00003","volume":"5","author":"DM Schreinemachers","year":"1994","unstructured":"D.M. Schreinemachers, and R.B. Everson, Aspirin use and lung, colon, and breast cancer incidence in a prospective study, Epidemiol. 5:138 (1994).","journal-title":"Epidemiol"},{"key":"28_CR16","first-page":"97","volume":"7","author":"DC Farrow","year":"1998","unstructured":"D.C. Farrow, T.L. Vaughan, P.D. Hansten et al., Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer, Cancer Epid. Biom. & Prey. 7:97 (1998).","journal-title":"Biom. & Prey."},{"issue":"2","key":"28_CR17","first-page":"293","volume":"60","author":"BS Reddy","year":"2000","unstructured":"B.S. Reddy, Y. Hirose, R. Lubet, V. Steele, G. Kelloff, S. Paulson, K, Seibert, and C.V. Rao, Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis, Cancer Res. 60(2):293 (2000).","journal-title":"Cancer Res"},{"key":"28_CR18","first-page":"409","volume":"58","author":"T Kawamori","year":"1998","unstructured":"T. Kawamori, C.V. Rao, K. Seibert, and B.S. Reddy, Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis, Cancer Res. 58:409 (1998).","journal-title":"Cancer Res"},{"key":"28_CR19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/(SICI)1098-2744(199908)25:4<231::AID-MC1>3.0.CO;2-F","volume":"25","author":"SM Fischer","year":"1999","unstructured":"S.M. Fischer, H.H. Lo, G.B. Gordon et al., Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis, Molec. Carcinogenesis 25:231 (1999).","journal-title":"Carcinogenesis"},{"key":"28_CR20","unstructured":"J.L. Masferrer, K.M. Leahy, A.T. Koki et al., Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors, Cancer Res. (in press)."}],"container-title":["Advances in Experimental Medicine and Biology","Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation, and Radiation Injury, 5"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4615-0193-0_28","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T07:55:47Z","timestamp":1741334147000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4615-0193-0_28"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002]]},"ISBN":["9781461349600","9781461501930"],"references-count":20,"URL":"https:\/\/doi.org\/10.1007\/978-1-4615-0193-0_28","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002]]}}}